FOXO CEO reports change of control, debt restructuring, and plans for revenue growth

FOXO TECHNOLOGIES INC.

Shareholders meeting Jan 17, 2025 concluded 2024 acquisition agreements, resulting in change of control of company.
Restructured over $21M in shareholders' equity, turning deficit to meet NYSE continued listing requirements of >$4M equity.
Acquired businesses have potential to deliver >$20M profitable net revenues per annum; focus on rural hospital and behavioral health.
Converted approx $6M additional debt to equity via convertible preferred stock (not freely tradable).
Plan to monetize epigenetics division (FOXO Labs) and pursue additional acquisitions in healthcare, including senior living.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.